Q-omics provides the consensus-scored RBM44 profile across patient tissues and cancer cell-line models. RBM44 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, RBM44 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, RBM44 RNA expression shows 17,161 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BLCA, HNSC, and UVM as cancer lineages where RBM44 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RBM44 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RBM44 survival associations across molecular data types. RBM44 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RBM44 RNA expression–survival associations across cancer types. High RBM44 expression shows unfavorable associations in LUSC, KIRC, LGG, UVM and THCA, but favorable associations in BLCA. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify BLCA as the clearest survival context for RBM44 RNA expression.
This table summarizes RBM44 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for RBM44. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RBM44 shows lower tumor expression in KICH, BRCA, LUAD and THCA and higher tumor expression in HNSC and LIHC. The HNSC box plot shows higher RBM44 RNA expression in tumor versus normal tissue (log2 FC = +0.136, t-test p < 0.001).
This table shows molecular features associated with RBM44 in patient tissues and cancer cell lines. In patient samples, RBM44 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, RBM44 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
